Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
52 hedge funds and large institutions have $438M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 14 closing their positions.
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
16% more funds holding
Funds holding: 45 → 52 (+7)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
53% less capital invested
Capital invested by funds: $942M → $438M (-$503M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.2M |
| 2 |
BlackRock
New York
|
+$5.29M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.98M |
| 4 |
JP Morgan Chase
New York
|
+$4.17M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$27M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.8M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.28M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.38M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.9M |
SGTX Hedge Fund Activity: Q1 2021 in Review
52 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q1 2021, worth a combined $438M — down 53% from $942M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SGTX positions and 14 closed out — a net gain of 7 holders — while 9 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $10.2M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $27M sold.
- 52 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q1 2021, up from 45 in Q4 2020.
- Funds reported $438M of Sigilon Therapeutics, Inc. Common Stock stock for Q1 2021, down 53% quarter-over-quarter.
- 21 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q1 2021 and 14 closed out, a net change of +7 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $10.2M added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q1 2021 was Monashee Investment Management, an estimated $27M sold.
Based on aggregated 13F filings for Q1 2021.